NCT03598413 (PROTEIN) is a NA clinical trial of Omega-3 in Colorectal Cancer, sponsored by Royal Surrey County Hospital NHS Foundation Trust.

Who is sponsoring NCT03598413?

NCT03598413 is sponsored by Royal Surrey County Hospital NHS Foundation Trust.

What drugs are being tested in NCT03598413?

Interventions in NCT03598413: Omega-3.

What condition does NCT03598413 study?

NCT03598413 studies Colorectal Cancer, Nutritional Deficiency, Infected Wound, Surgical Site Infection, Complication, Postoperative, Surgery, Surgery--Complications, Sarcopenia, Phagocytic Dysfunction.

Is NCT03598413 still recruiting?

NCT03598413 is currently completed. Last updated 28 September 2022.

Last reviewed 2022-09-28 · How we verify

NCT03598413: PROTEIN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PeRioperative Omega Three and the Effect on ImmuNity

Completed NA Last updated 28 September 2022

What this trial tests

NA trial testing Omega-3 in Colorectal Cancer in 40 participants. Completed in 19 September 2019.

Timeline

16 July 2018

Primary endpoint
19 September 2019

19 September 2019

Quick facts

Lead sponsor	Royal Surrey County Hospital NHS Foundation Trust
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	single
Primary purpose	prevention
Enrollment	40
Start date	16 July 2018
Primary completion	19 September 2019
Estimated completion	19 September 2019
Sites	1 location across United Kingdom

Drugs / interventions tested

Omega-3

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →
Nutritional Deficiency — all drugs for Nutritional Deficiency →
Infected Wound — all drugs for Infected Wound →
Surgical Site Infection — all drugs for Surgical Site Infection →

Sponsor

Royal Surrey County Hospital NHS Foundation Trust

Who can join

18 and older, any sex, with Colorectal Cancer or Nutritional Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bowel cancer is the second most common cause of cancer-related death in the UK, with 50,000 new cases and over 15,000 deaths annually. Surgery is the mainstay of treatment and the most common complications are an infection of the wound or lungs. These can lengthen hospital stay, reduce the quality of life, and even increase the risk of death. Bowel cancer patients are often malnourished. Optimising nutrition with supplements such as fish-oils can improve the immune response of patients, helping prevent such complications, shorten hospital stay, improve quality of life and overall survival.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Omega-3

Trials testing the same drug.

NCT07136519 — Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma · Phase 2 · not yet recruiting
NCT06538324 — Response to an Intervention With Omega-3 (RIO - Study) · NA · completed
NCT05990712 — The Effect of a Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammator · Phase 4 · unknown
NCT05711810 — Medicine-induced Cardiac Hemodialysis on COVID-19 · Phase 4 · completed
NCT07365553 — Omega-3, Autism Spectrum Disorder (ASD) · NA · recruiting

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Royal Surrey County Hospital NHS Foundation Trust trials

Trials by the same sponsor.

NCT07210502 — Side Effects of Low Dose Rate Brachytherapy and Ultra-hypofractionated Radiotherapy in Low to Intermediate Risk Prostate · NA · not yet recruiting
NCT06638593 — MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Masses ≤ 8cm. · NA · recruiting
NCT07046507 — The Exploratory Handheld Optical Coherence Tomography Study in Wilson's Disease · NA · completed
NCT06613256 — Characterisation of Endothelial Cells in Different Inflammatory Pathologies · recruiting
NCT06210724 — FIT in Diverticulitis · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03598413 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Royal Surrey County Hospital NHS Foundation Trust
Last refreshed: 28 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03598413.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing